Consider using PABA, a member of the B vitamin family, to your Peyronie’s treatment plan. It is very popular due to its well-documented and researched anti-fibrotic (anti-scar) effect in the body, as shown in numerous studies.
Many research studies support the use of PABA in treatment of PD because of its anti-fibrotic (anti-scar) effect in the body. For this reason it is used to treat certain skin conditions in which fibrosis, inelasticity or thickening of the skin occurs. Because of this clinical connection, PABA has long been such a great Peyronie’s treatment.
The reputed anti-fibrotic action of PABA may be due to its stimulation of increased oxygen uptake at the tissue level, which enhances the oxygen-dependent monoamine oxidase activity that in turn prevents or causes regression of tissue fibrosis. Aminobenzoate potassium is used medically to treat fibrosis, a condition in which the skin and underlying tissues tighten and become less flexible. This condition occurs in such diseases as Peyronie’s disease, dermatomyositis, morphea, scleroderma, and linear scleroderma. It is also used to treat non-suppurative inflammation that occurs in such diseases as dermatomyositis, pemphigus, and again, Peyronie’s disease. Supporting this idea, from the world literature we find reports of 2,752 cases treated with Potaba by 1996 that have shown improvement in 60% of the cases studied, with a range of improvement from 10% to 82% depending on the study, and a reported median failure rate of 40%.(2) The wide variation of success (10% to 82%) in the review is a reflection of the wide variance of the PD process, once again confirming this is a very difficult condition to study and determine success rates.